Key result
Text contains only an editorial board listing with no clinical data on growth hormone.
Why the study?
Growth hormone levels decrease with age while osteoarthritis increases, suggesting growth hormone may be related to the occurrence, development, and treatment of osteoarthritis.
This review explores the relationship between growth hormone and osteoarthritis, suggesting potential feasibility of treating OA with GH.
Answers are grounded in this paper and cite their sources.
No clinical data in this editorial listing; leaves open feasibility of growth hormone for osteoarthritis.
Osteoarthritis (OA), a chronic joint disease characterized by primary or secondary degeneration of articular cartilage and bone dysplasia, is associated with various risk factors and is the leading cause of musculoskeletal pain and disability, severely impacting the quality of life. Growth hormone (GH), secreted by the anterior pituitary gland, is essential in mediating the growth and development of bone and cartilage. Reportedly, osteoarthritis increases, and the growth hormone decreases with age. A negative correlation between GH and OA suggests that GH may be related to the occurrence and development of OA. Considering that abnormal growth hormone levels can lead to many diseases related to bone growth, we focus on the relationship between GH and OA. In this review, we will explain the effects of GH on the growth and deficiency of bone and cartilage based on the local pathological changes of osteoarthritis. In addition, the potential feasibility of treating OA with GH will be further explored and summarized.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2024) studied Osteoarthritis. Growth Hormone was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: